Detalhe da pesquisa
1.
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys.
Drug Dev Ind Pharm
; 45(3): 387-394, 2019 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-30395728
2.
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.
Sci Rep
; 11(1): 19422, 2021 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34593832
3.
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.
Sci Rep
; 9(1): 14042, 2019 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31575982
4.
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.
Sci Rep
; 8(1): 4941, 2018 03 21.
Artigo
Inglês
| MEDLINE | ID: mdl-29563546
5.
Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines.
Int J Cancer
; 112(4): 669-77, 2004 Nov 20.
Artigo
Inglês
| MEDLINE | ID: mdl-15382049